DOI QR코드

DOI QR Code

Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases

  • Moon, Jin Soo (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine)
  • Received : 2018.11.24
  • Accepted : 2018.11.28
  • Published : 2019.01.15

Abstract

The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as anti-tumor necrosis factor ${\alpha}$ have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.

Keywords

References

  1. Kelsen J, Baldassano RN. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis 2008;14 Suppl 2:S9-11.
  2. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39. https://doi.org/10.1002/ibd.21349
  3. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 2013;145:158-65.e2. https://doi.org/10.1053/j.gastro.2013.04.007
  4. Ong C, Aw MM, Liwanag MJ, Quak SH, Phua KB. Rapid rise in the incidence and clinical characteristics of pediatric inflammatory bowel disease in a South-East Asian cohort in Singapore, 1994-2015. J Dig Dis 2018;19:395-403. https://doi.org/10.1111/1751-2980.12641
  5. Hong SJ, Cho SM, Choe BH, Jang HJ, Choi KH, Kang B, et al. Characteristics and incidence trends for pediatric inflammatory bowel disease in Daegu-Kyungpook province in Korea: a multi-center study. J Korean Med Sci 2018;33:e132. https://doi.org/10.3346/jkms.2018.33.e132
  6. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-22. https://doi.org/10.1053/j.gastro.2008.06.081
  7. Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am 2009;38:611-28. https://doi.org/10.1016/j.gtc.2009.07.010
  8. Rinawi F, Assa A, Hartman C, Mozer Glassberg Y, Friedler VN, Rosenbach Y, et al. Incidence of bowel surgery and associated risk factors in pediatric-onset Crohn's disease. Inflamm Bowel Dis 2016;22:2917-23. https://doi.org/10.1097/MIB.0000000000000937
  9. Ruemmele FM, Turner D. Differences in the management of pediatric and adult onset ulcerative colitis: lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J Crohns Colitis 2014;8:1-4. https://doi.org/10.1016/j.crohns.2013.10.006
  10. Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014;63:423-32. https://doi.org/10.1136/gutjnl-2012-303864
  11. Jakobsen C, Bartek J Jr, Wewer V, Vind I, Munkholm P, Groen R, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease: a population-based study. Aliment Pharmacol Ther 2011;34:1217-24. https://doi.org/10.1111/j.1365-2036.2011.04857.x
  12. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-13. https://doi.org/10.1053/j.gastro.2008.06.079
  13. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40. https://doi.org/10.1016/j.jpeds.2004.08.043
  14. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014;147:990-1007.e3. https://doi.org/10.1053/j.gastro.2014.07.023
  15. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45. https://doi.org/10.1056/NEJMoa0907206
  16. Shim JO, Hwang S, Yang HR, Moon JS, Chang JY, Ko JS, et al. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis. Eur J Gastroenterol Hepatol 2013;25:1235-40. https://doi.org/10.1097/meg.0b013e328361a4f9
  17. Shim JO, Seo JK. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations. J Hum Genet 2014;59:337-41. https://doi.org/10.1038/jhg.2014.32
  18. Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013;131:825-30. https://doi.org/10.1016/j.jaci.2012.09.025
  19. Ko JS. Is infantile inflammatory bowel disease curable with hematopoietic stem cell transplantation? Korean J Gastroenterol 2013;62:313-4. https://doi.org/10.4166/kjg.2013.62.5.313
  20. Snapper SB. Very-early-onset inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2015;11:554-6.
  21. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21. https://doi.org/10.1002/ibd.21493
  22. Kim KY, Lee EJ, Kim JW, Moon JS, Jang JY, Yang HR, et al. Higher Morbidity of monogenic inflammatory bowel disease compared to the adolescent onset inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr 2018;21:34-42. https://doi.org/10.5223/pghn.2018.21.1.34
  23. Tsianos EV, Katsanos KH, Tsianos VE. Role of genetics in the diagnosis and prognosis of Crohn's disease. World J Gastroenterol 2012;18:105-18. https://doi.org/10.3748/wjg.v18.i2.105
  24. Bianco AM, Girardelli M, Tommasini A. Genetics of inflammatory bowel disease from multifactorial to monogenic forms. World J Gastroenterol 2015;21:12296-310. https://doi.org/10.3748/wjg.v21.i43.12296
  25. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2015;13:1042-50.e2. https://doi.org/10.1016/j.cgh.2013.09.006
  26. Kang B, Choe YH. Early biologic treatment in pediatric Crohn's disease: catching the therapeutic window of opportunity in early disease by treat-to-target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. https://doi.org/10.5223/pghn.2018.21.1.1
  27. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-207. https://doi.org/10.1016/j.crohns.2014.04.005
  28. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47. https://doi.org/10.1097/00005176-199105000-00005
  29. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. https://doi.org/10.1053/j.gastro.2007.05.029
  30. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment: shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69. https://doi.org/10.1111/j.1365-2036.2011.04598.x
  31. Noh SY, Oh SY, Kim SH, Kim HY, Jung SE, Park KW. Fifteen-year-old colon cancer patient with a 10-year history of ulcerative colitis. World J Gastroenterol 2013;19:2437-40. https://doi.org/10.3748/wjg.v19.i15.2437
  32. Philpott JR, Kurowski JA. Challenges in transitional care in inflammatory bowel disease: a review of the current literature in transition readiness and outcomes. Inflamm Bowel Dis 2019;25:45-55. https://doi.org/10.1093/ibd/izy207
  33. van Rheenen PF, Aloi M, Biron IA, Carlsen K, Cooney R, Cucchiara S, et al. European Crohn's and Colitis Organisation topical review on transitional care in inflammatory bowel disease. J Crohns Colitis 2017;11:1032-8. https://doi.org/10.1093/ecco-jcc/jjx010
  34. Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, et al. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut 2017;66:988-1000. https://doi.org/10.1136/gutjnl-2016-313000

Cited by

  1. COVID-19 and pediatric inflammatory bowel disease: How to manage it? vol.75, 2020, https://doi.org/10.6061/clinics/2020/e1962
  2. Outcomes of Initial Subtotal Colectomy for Pediatric Inflammatory Bowel Disease vol.255, 2019, https://doi.org/10.1016/j.jss.2020.05.026
  3. How Can We Do Transition Successfully from Pediatric to Adult Clinics in Inflammatory Bowel Disease? vol.77, pp.5, 2019, https://doi.org/10.4166/kjg.2021.065
  4. Gastrointestinal involvement in paediatric COVID-19 - from pathogenesis to clinical management: A comprehensive review vol.27, pp.23, 2019, https://doi.org/10.3748/wjg.v27.i23.3303